&w=3840&q=100)
Dell launches Alienware and Plus series laptops in India: Price and specs
Price and availability
Alienware 18 Area-51: Starts at Rs 3,14,990
Alienware 16 Area-51: Starts at Rs 3,09,990
Alienware 16X Aurora: Starts at Rs 1,76,990
Dell 16 Plus: Starts at Rs 76,400
Dell 14 2-in-1 Plus: Starts at Rs 87,670
Dell 14 Plus: Starts at Rs 76,940
All models are available via Dell's official website, Dell Exclusive Stores, select retail outlets such as Croma, Reliance Retail, Vijay Sales, and e-commerce platforms.
Alienware Area-51 (16 and 18)
Designed for gamers seeking high-performance hardware, the Alienware 16 and 18 Area-51 models are powered by Intel Core Ultra 9 275HX processors paired with up to NVIDIA GeForce RTX 5090 GPUs. The notebooks feature a cryo-tech cooling system, claimed to improve airflow by 37 per cent and reduce fan noise by 15 per cent.
Both models sport WQXGA displays with up to 300Hz refresh rate, 500 nits brightness, NVIDIA G-SYNC, and Dolby Atmos quad speakers. Design highlights include a Cherry Ultra Low-Profile keyboard, AlienFX touchpad, 4K webcam, Zero Hinge chassis, and Liquid Teal finish.
Specifications
Alienware 16X Aurora
The Alienware 16X Aurora features a 16-inch WQXGA display with 240Hz refresh rate, NVIDIA G-SYNC, and 500 nits brightness. Powered by up to an Intel Core Ultra 9 275Hx processor and NVIDIA GeForce RTX 5070 GPU, it incorporates a Cryo-Chamber cooling system using ultra-thin fans and copper heat pipes.
Specifications
Display: 16-inch WQXGA, 240Hz, 500 nits, G-SYNC
CPU: Intel Core Ultra 9 275Hx
GPU: Up to NVIDIA GeForce RTX 5070
RAM: Up to 64GB DDR5
Storage: Up to 2TB PCIe NVMe Gen4 SSD
Webcam: FHD HDR with IR and dual-array microphones
Battery: 90Whr, 6-cell
Dell 14 Plus, 14 2-in-1 Plus, and 16 Plus
These models are built for content creators and professionals, featuring AMD Ryzen AI 7 350 processors with Radeon 860M graphics, Dolby Vision displays, and Dolby Atmos audio.
Dell 14 Plus: Specifications
Display: 14-inch QHD+ (2560x1600), 120Hz, Dolby Vision
RAM: Up to 32GB LPDDR5x
Storage: Up to 2TB SSD
Webcam: FHD with AI noise reduction and privacy shutter
Battery: 64Whr
Dell 14 2-in-1 Plus: Specifications
Display: 14-inch FHD+ touchscreen, 60Hz, active pen support
RAM: 16GB LPDDR5x
Storage: Up to 2TB SSD
Webcam: FHD with AI noise reduction and privacy shutter
Battery: 64Whr
Dell 16 Plus: Specifications
Display: 16-inch QHD+, 120Hz, Dolby Vision
RAM: Up to 32GB LPDDR5x
Storage: Up to 2TB SSD
Webcam: FHD with dual microphones
Battery: 64Whr
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
43 minutes ago
- Time of India
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.
Indian Express
an hour ago
- Indian Express
Two new campuses coming up, Ambedkar University set to shift from Kashmere Gate site
With two new campuses under construction in Northwest Delhi's Dheerpur and Rohini, Ambedkar University Delhi (AUD) is set to relocate from its heritage campus in Kashmere Gate. While the Dheerpur campus, spanning 4.95 acres, is being developed at a cost of Rs 1,199.02 crore, the Rohini campus, spread across 20 acres, will be set up for a cost of Rs 1,107.56 crore, The Indian Express has learnt. Both projects received statutory clearances in 2022, and the construction is underway. Vice-Chancellor Anu Singh Lather said the move was necessitated by infrastructural limitations and long-term maintenance costs at the existing site. 'The university building that we are functioning out of is a very old heritage building. We have maintained it well, but we will have to move out of here soon,' said Lather. 'It will take at least a couple of years for the construction of the new campuses to end and for us to relocate.' The current campus at Lothian Road in Kashmere Gate sits on a 3-acre site housing a 400-year-old building complex. According to the university's website, it has 'well-stocked libraries, reading rooms, online journals and computer labs,' as well as 'classrooms equipped with audio-visual equipment and WiFi connectivity'. Hostel facilities are available only for women. In addition to Kashmere Gate, AUD has been operating a 6.5-acre campus in Karampura on Shivaji Marg since 2016-17. Originally housing Deen Dayal Upadhyaya College and before that Shivaji College, the Karampura campus has been retrofitted with modern infrastructure. 'The Karampura campus has all the facilities that the Kashmere Gate campus have — technology-enabled AC classrooms, library, computer labs, student activity areas, playgrounds and cafeteria,' the university website states. Currently, over 800 students study at Karampura campus, which is also home to the School of Global Affairs (since 2018), and is expected to house the School of Vocational Studies and the School of Law and Governance in the coming years. A training kitchen and restaurant have also been set up for students of tourism and hospitality programmes. Established in 2008 by the Delhi government, AUD focuses on the humanities and social sciences and is expanding to accommodate growing academic and infrastructural needs.
Economic Times
an hour ago
- Economic Times
Stock Radar: M&M likely to break out from 1-year consolidation range; time to buy?
Mahindra & Mahindra Ltd (M&M), part of the automobile industry, has been consolidating in a range for almost a year now and chart patterns suggest that a breakout is likely in the near term traders can look to buy stock now or on dips for a possible target of Rs 3,650 in the next 2-4 months, suggest automobile stock hit a high of Rs 3,276 on February 10, 2025. However, the stock has remained confined in a range where Rs
